The article offers an introduction to the ongoing trends within the orphan drug market, focusing on the leading pharmaceutical players in this field. A growing number of companies have turned to deal-making activity with specialist firms in an effort to secure promising pipeline candidates. Datamonitor has identified 8 potential takeover targets for Big Pharma, which could enable rapid sales growth in the orphan drug market.
Net orphan drug sales difference, by company ($m), 2011–17
Sanofi's acquisition of Genzyme, a global leader in lysosomal storage disorder (LSD) enzyme replacement therapies
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: